| Literature DB >> 29392083 |
Nathalie K Zgheib1, Fatima Sleiman1, Lara Nasreddine2, Mona Nasrallah3, Nancy Nakhoul3, Hussain Isma'eel3, Hani Tamim3,4.
Abstract
In Lebanon, data stemming from national cross-sectional surveys indicated significant increasing trends in the prevalence of cardiovascular diseases and associated behavioral and age-related risk factors. To our knowledge, no data are available on relative telomere length (RTL) as a potential biomarker for age-related diseases in a Lebanese population. The aim of this study was to evaluate whether there is an association between RTL and demographic characteristics, lifestyle habits and diseases in the Lebanese. This was a cross-sectional study of 497 Lebanese subjects. Peripheral blood RTL was measured by amplifying telomere and single copy gene using real-time PCR. Mean ± SD RTL was 1.42 ± 0.83, and it was categorized into 3 tertiles. Older age (P=0.002) and wider waist circumference (WC) (P=0.001) were statistically significantly associated with shorter RTL. Multinomial logistic regression showed that subjects who had some level of sleeping difficulty had a statistically significantly shorter RTL when compared to those with no sleeping difficulties at all [OR (95% CI): 2.01 (1.11-3.62) in the first RTL tertile]. Importantly, statistically significantly shorter RTL was found with every additional 10 cm of WC [OR (95% CI): 1.30 (1.11-1.52) for first RTL tertile]. In addition, and after performing the multivariate logistic regression and adjusting for "predictors" of RTL, the odds of having hypertension or being treated for hypertension were higher in patients who had shorter RTL: OR (95% CI): 2.45 (1.36-4.44) and 2.28 (1.22-4.26) in the first RTL tertiles respectively with a similar trend, though not statistically significant, in the second RTL tertiles. This is the first study in Lebanon to show an association between age, central obesity, poor sleep and hypertension and RTL. It is hoped that telomere length measurement be potentially used as a biomarker for biological age and age-related diseases and progression in the Lebanese.Entities:
Keywords: Aging; Hypertension; Obesity; Relative telomere length; Sleep
Year: 2018 PMID: 29392083 PMCID: PMC5772860 DOI: 10.14336/AD.2017.0310
Source DB: PubMed Journal: Aging Dis ISSN: 2152-5250 Impact factor: 6.745
Figure 1.Correlation of relative telomere length with age and waist circumference
Scatter plots showing the correlation of age (A) and waist circumference (B) with the relative telomere length of peripheral leucocyte blood respectively in males and females. The grey line and (×) represent the males (n=178) and the black line and (o) represent the females (n=319). The P-values were calculated from the linear regression analyses of the relationships between age, waist circumference and RTL in males and females, and the Pearson correlation was used.
The association of RTL with baseline characteristics and lifestyle.
| RTL | |||||
|---|---|---|---|---|---|
| <1.06 | 1.06 - 1.432 | >1.432 | p-value | ||
| 48.56 ± 14.75 | 44.70 ± 15.01 | 42.92 ± 15.03 | 0.002 | ||
| < | 43 (25.9) | 61 (37.0) | 75 (45.2) | 0.009 | |
| 91 (54.8) | 78 (47.3) | 67 (40.42) | |||
| > | 32 (19.3) | 26 (15.8) | 24 (14.5) | ||
| Female | 105 (63.3) | 106 (64.2) | 108 (65.1) | 0.94 | |
| 106 (63.9) | 114 (69.1) | 109 (65.7) | 0.17 | ||
| 28 (16.9) | 33 (20.0) | 37 (22.3) | |||
| 32 (19.3) | 18 (10.9) | 20 (12.0) | |||
| < | 58 (35.4) | 48 (29.4) | 46 (27.7) | 0.31 | |
| 58 (35.4) | 55 (33.7) | 56 (33.7) | |||
| ≥ | 35 (21.3) | 41 (25.2) | 52 (31.3) | ||
| 13 (7.9) | 19 (11.7) | 12 (7.2) | |||
| 74 (44.6) | 55 (33.3) | 52 (31.7) | 0.03 | ||
| 30 (18.1) | 56 (33.9) | 48 (29.3) | |||
| 43 (25.9) | 39 (23.6) | 44 (26.8) | |||
| 19 (11.4) | 15 (9.1) | 20 (12.2) | |||
| 1.52 ± 0.84 | 1.55 ± 0.90 | 1.50 ± 0.91 | 0.86 | ||
| 104 (62.7) | 112 (67.9) | 103 (62.0) | 0.48 | ||
| 74 (44.6) | 77 (46.7) | 63 (38.0) | 0.25 | ||
| 46 (27.7) | 44 (26.7) | 51 (30.7) | 0.70 | ||
| 34 (20.5) | 35 (21.2) | 26(15.7) | 0.38 | ||
| 133 (80.1) | 136 (82.4) | 130 (78.3) | 0.64 | ||
| 29.96 ± 5.73 | 28.92 ± 5.65 | 28.40 ± 5.94 | 0.045 | ||
| ≥ | 76 (45.8) | 69 (41.8) | 62 (37.3) | 0.30 | |
| 98.91 ± 14.46 | 95.87 ± 17.52 | 92.75 ± 14.12 | 0.001 | ||
| 30.29 ± 11.28 | 28.24 ± 11.09 | 27.30 ± 12.06 | 0.05 | ||
| 26.45 ± 6.80 | 26.24 ± 6.24 | 26.19 ± 6.19 | 0.93 | ||
| 76 (45.8) | 82 (49.7) | 80 (48.2) | 0.97 | ||
| 54 (32.5) | 49 (29.7) | 51 (30.7) | |||
| 36 (21.7) | 34 (20.6) | 35 (21.1) | |||
| 29 (17.5) | 26 (15.8) | 24 (14.5) | 0.75 | ||
| 137 (82.5) | 139 (84.2) | 142 (85.5) | |||
| ≤ | 26 (15.7) | 18 (10.9) | 23 (13.9) | 0.26 | |
| 43 (25.9) | 47 (28.5) | 40 (24.1) | |||
| 50 (30.1) | 37 (22.4) | 44 (26.5) | |||
| 21 (12.7) | 37 (22.4) | 34 (20.5) | |||
| 16 (9.6) | 13 (7.9) | 19 (11.4) | |||
| ≥ | 10 (6.0) | 13 (7.9) | 6 (3.6) | ||
| ≤ | 23 (13.9) | 20 (12.1) | 21 (12.7) | 0.80 | |
| 30 (18.1) | 32 (19.4) | 30 (18.1) | |||
| 37 (22.3) | 31 (18.8) | 31 (18.7) | |||
| 26 (15.7) | 35 (21.2) | 37 (22.3) | |||
| 20 (12.0) | 23 (13.9) | 27 (16.3) | |||
| ≥ | 30 (18.1) | 24 (14.5) | 20 (12.0) | ||
| 61 (37.4) | 60 (37.0) | 57 (35.2) | 0.83 | ||
| 48 (29.4) | 40 (24.7) | 46 (28.4) | |||
| 54 (33.1) | 62 (38.3) | 59 (36.4) | |||
| 32 (19.3) | 40 (24.2) | 50 (30.1) | 0.03 | ||
| 63 (38.0) | 42 (25.5) | 50 (30.1) | |||
| 71 (42.8) | 83 (50.3) | 66 (39.8) | |||
N (%)
Widow, divorced, or engaged
The association of RTL with chronic diseases and laboratory measurements.
| RTL | |||||
|---|---|---|---|---|---|
| <1.06 | 1.06 - 1.432 | >1.432 | p-value | ||
| Diabetes | |||||
| Definite diabetes | 25 (15.1) | 30 (18.2) | 20 (12.0) | 0.30 | |
| Self-reported diabetes or hyperglycemia diagnosis | 24 (14.5) | 27 (16.4) | 13 (7.8) | 0.05 | |
| Diabetes treatment | 26 (15.7) | 23 (13.9) | 12 (7.2) | 0.05 | |
| Fasting blood sugar (mg/dL) | Abnormal | 90 (54.2) | 81 (49.1) | 76 (45.8) | 0.30 |
| Insulin (µIU/mL) | Mean (±SD) | 28.28 ± 11.10 | 29.68 ± 18.59 | 28.29 ± 19.46 | 0.74 |
| HbA1C (%) | Mean (±SD) | 5.97 ± 1.38 | 6.02 ± 1.38 | 5.80 ± 1.30 | 0.32 |
| C peptide (ng/dL) | Mean (±SD) | 3.34 ± 1.51 | 3.01 ± 1.28 | 3.01 ± 1.59 | 0.07 |
| Hypertension (HTN) | |||||
| Definite HTN | 73 (44.2) | 61 (37.0) | 47 (28.3) | 0.01 | |
| Self-reported HTN diagnosis | 56 (33.7) | 39 (23.6) | 23 (13.9) | <0.0001 | |
| HTN treatment | 52 (31.3) | 36 (21.8) | 22 (13.3) | <0.0001 | |
| Systolic blood pressure (mm/Hg) | Mean (±SD) | 122.38 ± 17.82 | 123.01 ± 21.22 | 119.41 ± 18.34 | 0.19 |
| Diastolic blood pressure (mm/Hg) | Mean (±SD) | 75.38 ± 9.31 | 74.95 ± 10.81 | 73.94 ± 9.76 | 0.40 |
| Dyslipidemia | |||||
| Self-reported dyslipidemia diagnosis | 53 (31.9) | 35 (21.2) | 31 (18.7) | 0.01 | |
| Dyslipidemia treatment | 43 (25.9) | 28 (17.0) | 23 (13.9) | 0.02 | |
| HDL (mg/dL) | Mean (±SD) | 50.04 ± 15.02 | 49.47 ± 14.29 | 49.45 ± 15.22 | 0.92 |
| LDL (mg/dL) | Mean (±SD) | 110.64 ± 35.45 | 111.65 ± 42.53 | 104.08 ± 34.34 | 0.14 |
| Triglycerides (mg/dL) | Mean (±SD) | 142.23 ± 70.39 | 151.04 ± 141.95 | 131.12 ± 79.07 | 0.21 |
| Metabolic Syndrome | |||||
| Metabolic Syndrome | 90 (54.2) | 79 (47.9) | 85 (51.2) | 0.51 | |
| Atherosclerotic cardiovascular disease (ASCVD) 10yrs Risk | |||||
| ASCVD 10yrs Risk (%) | Mean (±SD) | 7.82 ± 11.72 | 7.82 ± 14.27 | 4.94 ± 7.03 | 0.04 |
| Others | |||||
| CRP (mg/L) | Mean (±SD) | 13.07 ± 8.80 | 13.01 ± 13.35 | 10.28 ± 6.89 | 0.02 |
| Cortisol (µg/dL) | Mean (±SD) | 18.35 ± 10.43 | 19.14 ± 13.95 | 16.89 ± 10.59 | 0.22 |
N (%)
Subjects who were diagnosed with diabetes and/or both fasting blood sugar (FBS) was ≥126 mg/dL and HbA1C was ≥6.5%.
Subjects who were diagnosed with hypertension or had an abnormal blood pressure reading upon recruitment (systolic blood pressure≥140 mm/Hg or diastolic blood pressure≥90 mm/Hg).
Definition was based on Alberti et al. Circulation 2009.
Definition was based on the 2013 ACC/AHA guideline.
Stepwise multinomial logistic regression of potentially significant predictors of RTL including waist circumference as a marker for obesity with RTL
| RTL | |||||
|---|---|---|---|---|---|
| ≤1.060 | 1.060 - 1.432 | >1.432 | |||
| Variables | OR ( 95 % CI ) | P-value | OR ( 95 % CI ) | P-value | |
| Education - Intermediate school | 0.50 (0.28 - 0.89) | 0.02 | 1.22 (0.71 - 2.11) | 0.47 | Reference |
| Education - Secondary school/technical diploma | 0.84 (0.47 - 1.48) | 0.55 | 1.02 (0.57 - 1.83) | 0.95 | Reference |
| Education - University degree | 0.98 (0.45 - 2.11) | 0.96 | 0.99 (0.44 - 2.23) | 0.99 | Reference |
| Waist circumference -WC (cm) | 1.30 (1.11 - 1.52) | 0.001 | 1.17 (1.00 - 1.37) | 0.05 | Reference |
| Any Sleeping Difficulty - Rarely, sometimes, or frequently | 2.01 (1.11 - 3.62) | 0.02 | 1.04 (0.58 - 1.88) | 0.88 | Reference |
| Any Sleeping Difficulty - Almost always | 1.73 (0.97 - 3.08) | 0.06 | 1.55 (0.91 - 2.67) | 0.11 | Reference |
Age (reference: <40); Education (reference: No schooling/primary school); Waist circumference (per unit increase of 10); Any sleeping Difficulty (reference: Never). Body mass index -BMI was not included due to collinearity with WC.
Stepwise multivariate logistic regression of RTL tertiles with chronic disease and laboratory values with and without adjustment with potentially significant predictors of RTL1
| ≤1.060 | P-value | RTL | P-value | >1.432 | |
|---|---|---|---|---|---|
| Diabetes | |||||
| Definite diabetes | |||||
| 25 (15.1) | 30 (18.2) | 20 (12.0) | |||
| 1.29 (0.69 - 2.43) | 0.42 | 1.62 (0.88 - 2.99) | 0.12 | Reference | |
| 0.76 (0.38 - 1.52) | 0.43 | 1.29 (0.65 - 2.56) | 0.46 | Reference | |
|
| |||||
| Diabetes diagnosis | |||||
| 24 (14.5) | 27 (16.4) | 13 (7.8) | |||
| 1.99 (0.97 - 4.06) | 0.06 | 2.30 (1.14 - 4.64) | 0.02 | Reference | |
| 1.31 (0.61 - 2.81) | 0.48 | 1.94 (0.91 - 4.13) | 0.09 | Reference | |
|
| |||||
| Diabetes treatment | |||||
| 26 (15.7) | 23 (13.9) | 12 (7.2) | |||
| 2.38 (1.16 - 4.90) | 0.02 | 2.08 (1.00 - 4.33) | 0.05 | Reference | |
| 1.67 (0.78 - 3.56) | 0.19 | 1.71 (0.79 - 3.73) | 0.17 | Reference | |
|
| |||||
| Abnormal fasting blood sugar | |||||
| 90 (54.2) | 81 (49.1) | 76 (45.8) | |||
| 1.40 (0.91 - 2.16) | 0.12 | 1.14 (0.74 - 1.76) | 0.55 | Reference | |
| 0.92 (0.57 - 1.50) | 0.74 | 0.96 (0.59 - 1.56) | 0.88 | Reference | |
|
| |||||
| Insulin (µIU/mL) | |||||
| 28.28 ± 11.10 | 29.68 ± 18.59 | 28.29 ± 19.46 | |||
| -0.01 (-4.03; 4.02) | 1.00 | 1.40 (-2.66; 5.46) | 0.50 | Reference | |
| -2.34 (-6.20; 1.52) | 0.23 | -0.06 (-3.92; 3.81) | 0.98 | Reference | |
|
| |||||
| HbA1C (%) | |||||
|
| |||||
| 5.97 ± 1.38 | 6.02 ± 1.38 | 5.80 ± 1.30 | |||
| 0.16 (-0.13; 0.45) | 0.29 | 0.22 (-0.08; 0.51) | 0.15 | Reference | |
| -0.10 (-0.37; 0.17) | 0.48 | 0.09 (-0.18; 0.36) | 0.50 | Reference | |
|
| |||||
| C-peptide (ng/dL) | |||||
| 3.34 ± 1.51 | 3.01 ± 1.28 | 3.01 ± 1.59 | |||
| 0.33 (0.0; 0.64) | 0.04 | 0.002 (-0.32; 0.32) | 0.99 | Reference | |
| 0.09 (-0.20; 0.38) | 0.55 | -0.12 (-0.41; 0.17) | 0.41 | Reference | |
| Hypertension (HTN) | |||||
| Definite HTN | |||||
| 73 (44.2) | 61 (37.0) | 47 (28.3) | |||
| 2.01 (1.27 - 3.17) | 0.003 | 1.48 (0.93 - 2.36) | 0.09 | Reference | |
| 1.42 (0.85 - 2.38) | 0.18 | 1.31 (0.77 - 2.23) | 0.31 | Reference | |
|
| |||||
| HTN diagnosis | |||||
| 56 (33.7) | 39 (23.6) | 23 (13.9) | |||
| 3.16 (1.83 - 5.46) | <0.0001 | 1.92 (1.09 - 3.40) | 0.02 | Reference | |
| 2.45 (1.36 - 4.44) | 0.003 | 1.71 (0.92 - 3.19) | 0.09 | Reference | |
|
| |||||
| HTN treatment | |||||
| 52 (31.3) | 36 (21.8) | 22 (13.3) | |||
| 2.99 (1.71 - 5.20) | <0.0001 | 1.83 (1.02 - 3.27) | 0.04 | Reference | |
| 2.28 (1.22 - 4.26) | 0.01 | 1.61 (0.83 - 3.11) | 0.15 | Reference | |
|
| |||||
| Systolic blood pressure (mm/Hg) | |||||
| 122.38 ± 17.82 | 123.01 ± 21.22 | 119.41 ± 18.34 | |||
| 2.97 (-1.18; 7.12) | 0.16 | 3.60 (-0.54; 7.75) | 0.09 | Reference | |
| -0.20 (-3.95; 3.56) | 0.25 | 2.17 (-1.54; 5.88) | 0.25 | Reference | |
|
| |||||
| Diastolic blood pressure (mm/Hg) | |||||
| 75.38 ± 9.31 | 74.95 ± 10.81 | 73.94 ± 9.76 | |||
| 1.44 (-0.72; 3.60) | 0.19 | 1.01 (-1.15; 3.17) | 0.36 | Reference | |
| -0.20 (-2.21; 1.82) | 0.85 | 0.28 (-1.71; 2.27) | 0.78 | Reference | |
|
| |||||
| Dyslipidemia | |||||
| Dyslipidemia diagnosis | |||||
| 53 (31.9) | 35 (21.2) | 31 (18.7) | |||
| 2.04 (1.23 - 3.40) | 0.01 | 1.17 (0.68 - 2.01) | 0.56 | Reference | |
| 1.42 (0.82 - 2.47) | 0.21 | 0.94 (0.52 - 1.70) | 0.84 | Reference | |
|
| |||||
| Dyslipidemia treatment | |||||
| 43 (25.9) | 28 (17.0) | 23 (13.9) | |||
| 2.17 (1.24 - 3.81) | 0.01 | 1.27 (0.70 - 2.31) | 0.43 | Reference | |
| 1.59 (0.87 - 2.91) | 0.13 | 1.03 (0.54 - 1.96) | 0.92 | Reference | |
|
| |||||
| HDL (mg/dL) | |||||
| 50.04 ± 15.02 | 49.47 ± 14.29 | 49.45 ± 15.22 | |||
| 0.59 (-2.61 ; 3.79) | 0.72 | 0.02 (-3.19 ; 3.23) | 0.99 | Reference | |
| 2.05 (-1.10 ; 5.19) | 0.20 | 0.76 (-2.36 ; 3.88) | 0.63 | Reference | |
|
| |||||
| LDL (mg/dL) | |||||
| 110.64 ± 35.45 | 111.65 ± 42.53 | 104.08 ± 34.34 | |||
| 6.56 (-1.55 ; 14.67) | 0.11 | 7.57 (-0.56 ; 15.70) | 0.07 | Reference | |
| 2.65 (-5.40 ; 10.70) | 0.52 | 6.56 (-1.40 ; 14.53) | 0.11 | Reference | |
|
| |||||
| Triglycerides (mg/dL) | |||||
| 142.23 ± 70.39 | 151.04 ± 141.95 | 131.12 ± 79.07 | |||
| 11.11 (-10.92 ; 33.14) | 0.32 | 19.92 (-2.14 ; 41.98) | 0.08 | Reference | |
| 3.68 (-17.93 ; 25.29) | 0.74 | 13.42 (-7.94 ; 34.78) | 0.22 | Reference | |
|
| |||||
| Metabolic syndrome | |||||
| 90 (54.2) | 79 (47.9) | 85 (51.2) | |||
| 1.13 (0.73 - 1.74) | 0.58 | 0.87 (0.57 - 1.35) | 0.54 | Reference | |
| 0.87 (0.55 - 1.39) | 0.57 | 0.75 (0.47 - 1.19) | 0.22 | Reference | |
|
| |||||
| Atherosclerotic cardiovascular disease (ASCVD) 10yrs Risk | |||||
| 7.82 ± 11.72 | 7.82 ± 14.27 | 4.94 ± 7.03 | |||
| 2.88 (0.34 ; 5.42) | 0.03 | 2.88 (0.36 ; 5.41) | 0.02 | Reference | |
| 1.54 (-0.95 ; 4.04) | 0.22 | 2.39 (-0.05 ; 4.82) | 0.05 | Reference | |
|
| |||||
| Other | |||||
|
| |||||
| CRP (mg/L) | |||||
| 13.07 ± 8.80 | 13.01 ± 13.35 | 10.28 ± 6.89 | |||
| 2.78 (0.62 ; 4.95) | 0.01 | 2.73 (0.56 ; 4.90) | 0.01 | Reference | |
| 1.78 (-0.33 ; 3.89) | 0.10 | 2.38 (0.28 ; 4.49) | 0.03 | Reference | |
|
| |||||
| Cortisol (µg/dL) | |||||
| 18.35 ± 10.43 | 19.14 ± 13.95 | 16.89 ± 10.59 | |||
| 1.46 (-1.10 ; 4.03) | 0.26 | 2.25 (-0.34 ; 4.84) | 0.09 | Reference | |
| 1.94 (-0.62 ; 4.51) | 0.14 | 2.53 (-0.04 ; 5.11) | 0.05 | Reference | |
Stepwise regression with the following covariates: Age (reference: <40); Education (reference: No schooling/primary school); WC (per unit increase of 10); Any sleeping Difficulty (reference: Never).
Stepwise regression with the following covariates: Age (reference: <40); Education (reference: No schooling/primary school); Any sleeping Difficulty (reference: Never).
Stepwise regression with the following covariates: Education (reference: No schooling/primary school); WC (per unit increase of 10); Any sleeping Difficulty (reference: Never).
Stepwise multinomial logistic regression of potentially significant predictors of RTL including body mass index as a marker for obesity with RTL
| RTL | |||||
|---|---|---|---|---|---|
| ≤1.060 | 1.060 - 1.432 | >1.432 | |||
| Variables | OR (95 % CI ) | P-value | OR (95 % CI) | P-value | |
| Age - 40-60 years | 2.41 (1.45 - 4.02) | 0.001 | 1.35 (0.84 - 2.19) | 0.22 | Reference |
| Age - >60 years | 2.12 (1.06 - 4.23) | 0.03 | 1.25 (0.63 - 2.48) | 0.52 | Reference |
| Education - Intermediate school | 0.49 (0.27 - 0.88) | 0.02 | 1.19 (0.68 - 2.06) | 0.54 | Reference |
| Education - Secondary school or technical diploma | 0.88 (0.49 - 1.58) | 0.67 | 1.00 (0.55 - 1.82) | 1.00 | Reference |
| Education - University degree | 0.96 (0.45 - 2.06) | 0.91 | 0.90 (0.40 - 2.01) | 0.80 | Reference |
| Any sleeping difficulty - Rarely, sometimes, or frequently | 2.04 (1.13 - 3.69) | 0.02 | 1.04 (0.58 - 1.88) | 0.89 | Reference |
| Any sleeping difficulty - Almost always | 1.61 (0.90 - 2.86) | 0.11 | 1.49 (0.87 - 2.55) | 0.15 | Reference |
Age (reference: <40); Education (reference: No schooling/primary school); Body mass index -BMI (per unit increase of 1); Any sleeping Difficulty (reference: Never). Waist Circumference (WC) was not included due to collinearity with BMI.